SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in accordance with enrollment initiation TEL AVIV, Israel, Feb. 29,...

SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market TEL AVIV,...

New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...

The Spectrum Strategy Group Launches Season 2 of Autism in Real Life With Temple Grandin CAPE CORAL, Fla., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Ilia Walsh will launch the season with a conversation about employment with Temple Grandin. Dr. Temple Grandin of CSU has been named one of...